Alexandre Doussot1, Mithat Gonen2, Jimme K Wiggers3, Bas Groot-Koerkamp3, Ronald P DeMatteo3, David Fuks4, Peter J Allen3, Olivier Farges5, T Peter Kingham3, Jean Marc Regimbeau6, Michael I D'Angelica3, Daniel Azoulay7, William R Jarnagin8. 1. Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY; Department of Hepatobiliary Surgery and Liver Transplantation, Hôpital Henri Mondor, Assistance Publique-Hôpitaux de Paris, AP-HP, Créteil, France. 2. Department of Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY. 3. Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY. 4. Department of Digestive Pathology, Institut Mutualiste Montsouris, Paris Descartes University, Paris, France. 5. Department of Hepatobiliary Surgery, Hôpital Beaujon, Assistance Publique-Hôpitaux de Paris, AP-HP, Université Paris 7, Clichy, France. 6. Department of Surgery, CHU Amiens, Amiens, France. 7. Department of Hepatobiliary Surgery and Liver Transplantation, Hôpital Henri Mondor, Assistance Publique-Hôpitaux de Paris, AP-HP, Créteil, France. 8. Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY. Electronic address: jarnagiw@mskcc.org.
Abstract
BACKGROUND: Liver resection is the most effective treatment for intrahepatic cholangiocarcinoma. Recurrent disease is frequent; however, recurrence patterns are ill-defined and prognostic models are lacking. STUDY DESIGN: A primary cohort of 189 patients who underwent resection for intrahepatic cholangiocarcinoma was used for recurrence patterns analysis within and after 24 months. Based on independent factors for disease-free survival identified in Cox regression analysis, preoperative and postoperative models were developed using a recursive partitioning method. Models were externally validated using a multicenter cohort of 522 resected patients (Association Française de Chirurgie intrahepatic cholangiocarcinoma study group). RESULTS: Recurrence within 24 months most often involved the liver (82.7%), and most recurrences after 24 months were strictly extrahepatic (61.1%). In multivariable analysis of the primary cohort, independent preoperative factors for disease-free survival were tumor size and multifocality (based on imaging); tumor size, multifocality, vascular invasion, and lymph node metastases (based on pathology) were independent postoperative factors. The preoperative model allowed patient classification into low-risk and high-risk groups for recurrence. In the validation cohort (n = 522), high-risk patients had a greater likelihood of recurrence (hazard ratio = 2.17; 95% CI, 1.74-2.72; p < 0.001). The postoperative model included tumor size, vascular invasion, and positive nodal disease on pathology and classified patients in low-, intermediate-, and high-risk groups in the primary cohort. As compared with low-risk patients in the validation cohort, intermediate- and high-risk patients were more likely to experience recurrence (hazard ratio = 1.9; 95% CI, 1.41-2.47; p < 0.001 and hazard ratio = 2.99; 95% CI, 2.08-4.31; p < 0.001, respectively). CONCLUSIONS: Recurrence patterns are time dependent. Both models as developed and validated in this study classified patients in distinct recurrence risk groups, which can guide treatment recommendations.
BACKGROUND: Liver resection is the most effective treatment for intrahepatic cholangiocarcinoma. Recurrent disease is frequent; however, recurrence patterns are ill-defined and prognostic models are lacking. STUDY DESIGN: A primary cohort of 189 patients who underwent resection for intrahepatic cholangiocarcinoma was used for recurrence patterns analysis within and after 24 months. Based on independent factors for disease-free survival identified in Cox regression analysis, preoperative and postoperative models were developed using a recursive partitioning method. Models were externally validated using a multicenter cohort of 522 resected patients (Association Française de Chirurgie intrahepatic cholangiocarcinoma study group). RESULTS: Recurrence within 24 months most often involved the liver (82.7%), and most recurrences after 24 months were strictly extrahepatic (61.1%). In multivariable analysis of the primary cohort, independent preoperative factors for disease-free survival were tumor size and multifocality (based on imaging); tumor size, multifocality, vascular invasion, and lymph node metastases (based on pathology) were independent postoperative factors. The preoperative model allowed patient classification into low-risk and high-risk groups for recurrence. In the validation cohort (n = 522), high-risk patients had a greater likelihood of recurrence (hazard ratio = 2.17; 95% CI, 1.74-2.72; p < 0.001). The postoperative model included tumor size, vascular invasion, and positive nodal disease on pathology and classified patients in low-, intermediate-, and high-risk groups in the primary cohort. As compared with low-risk patients in the validation cohort, intermediate- and high-risk patients were more likely to experience recurrence (hazard ratio = 1.9; 95% CI, 1.41-2.47; p < 0.001 and hazard ratio = 2.99; 95% CI, 2.08-4.31; p < 0.001, respectively). CONCLUSIONS: Recurrence patterns are time dependent. Both models as developed and validated in this study classified patients in distinct recurrence risk groups, which can guide treatment recommendations.
Authors: Alexandre Doussot; Bas Groot-Koerkamp; Jimme K Wiggers; Joanne Chou; Mithat Gonen; Ronald P DeMatteo; Peter J Allen; T Peter Kingham; Michael I D'Angelica; William R Jarnagin Journal: J Am Coll Surg Date: 2015-04-24 Impact factor: 6.113
Authors: Omar Hyder; Ioannis Hatzaras; Georgios C Sotiropoulos; Andreas Paul; Sorin Alexandrescu; Hugo Marques; Carlo Pulitano; Eduardo Barroso; Bryan M Clary; Luca Aldrighetti; Cristina R Ferrone; Andrew X Zhu; Todd W Bauer; Dustin M Walters; Ryan Groeschl; T Clark Gamblin; J Wallis Marsh; Kevin T Nguyen; Ryan Turley; Irinel Popescu; Catherine Hubert; Stephanie Meyer; Michael A Choti; Jean-Francois Gigot; Gilles Mentha; Timothy M Pawlik Journal: Surgery Date: 2013-03-15 Impact factor: 3.982
Authors: Lucas M Boehm; Thejus T Jayakrishnan; John T Miura; Anthony J Zacharias; Fabian M Johnston; Kiran K Turaga; T Clark Gamblin Journal: J Surg Oncol Date: 2014-09-01 Impact factor: 3.454
Authors: Ioannis T Konstantinidis; Richard K G Do; David H Gultekin; Mithat Gönen; Lawrence H Schwartz; Yuman Fong; Peter J Allen; Michael I D'Angelica; Ronald P DeMatteo; David S Klimstra; Nancy E Kemeny; William R Jarnagin Journal: Ann Surg Oncol Date: 2014-03-25 Impact factor: 5.344
Authors: Fabio Bagante; Gaya Spolverato; Matthew Weiss; Sorin Alexandrescu; Hugo P Marques; Luca Aldrighetti; Shishir K Maithel; Carlo Pulitano; Todd W Bauer; Feng Shen; George A Poultsides; Oliver Soubrane; Guillaume Martel; B Groot Koerkamp; Alfredo Guglielmi; Endo Itaru; Timothy M Pawlik Journal: J Gastrointest Surg Date: 2017-04-19 Impact factor: 3.452
Authors: Fabio Bagante; Gaya Spolverato; Matthew Weiss; Sorin Alexandrescu; Hugo P Marques; Luca Aldrighetti; Shishir K Maithel; Carlo Pulitano; Todd W Bauer; Feng Shen; George A Poultsides; Olivier Soubrane; Guillaume Martel; B Groot Koerkamp; Alfredo Guglielmi; Endo Itaru; Andrea Ruzzenente; Timothy M Pawlik Journal: World J Surg Date: 2018-08 Impact factor: 3.352
Authors: H P Neeff; P A Holzner; M Menzel; P Bronsert; A Klock; S A Lang; S Fichtner-Feigl; U T Hopt; F Makowiec Journal: Chirurg Date: 2018-05 Impact factor: 0.955
Authors: Emily A Aherne; Linda M Pak; Debra A Goldman; Mithat Gonen; William R Jarnagin; Amber L Simpson; Richard K Do Journal: Abdom Radiol (NY) Date: 2018-10
Authors: Grace C Lee; Cristina R Ferrone; Kenneth K Tanabe; Keith D Lillemoe; Lawrence S Blaszkowsky; Andrew X Zhu; Theodore S Hong; Motaz Qadan Journal: Am J Surg Date: 2019-03-04 Impact factor: 2.565
Authors: Carlie S Sigel; Esther Drill; Yi Zhou; Olca Basturk; Gokce Askan; Linda M Pak; Efsevia Vakiani; Tao Wang; Thomas Boerner; Richard K G Do; Amber L Simpson; William Jarnagin; David S Klimstra Journal: Am J Surg Pathol Date: 2018-10 Impact factor: 6.394
Authors: Daniel R Waisberg; Rafael S Pinheiro; Lucas S Nacif; Vinicius Rocha-Santos; Rodrigo B Martino; Rubens M Arantes; Liliana Ducatti; Quirino Lai; Wellington Andraus; Luiz C D'Albuquerque Journal: Transl Gastroenterol Hepatol Date: 2018-09-12